学会発表
Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer
Hiroji Iwata, Naohito Yamamoto, Norikazu Masuda, Hiroko Bando, Katsumasa Kuroi, Shinji Ohno, Hiroi Kasai, Satoshi Morita, Takaki Sakurai, Masakazu Toi
St.Gallen Poster
Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study)
Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katsumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yasuhiro Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita, Masakazu Toi
2013 SABCS Poster
A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC, and TC-FEC as preoperative chemotherapy for hormone receptor-positive and HER2-negative primary breast cancer: Japan Breast Cancer Research Group (JBCRG) – 09
Nobuaki Sato, Norikazu Masuda, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka, and Masakazu Toi
2013 SABCS Poster
Safety of trastuzumab in HER2 positive primary breast cancer in Japan; Initial safety report for the large scale cohort study (JBCRG-C01)
Naohito Yamamoto, Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, Shoichiro Ohtani, Masato Takahashi, Kosuke Yamazaki, Makoto Kato, Shinji Ohno, Katumasa Kuroi, Kazuhiko Yamagami, Takashi Morimoto, Yoshie Hasegawa, Toshimi Takano, Takayuki Kadoya, Mitsuchika Hosoda, Hajime Abe, Satoshi Morita, Shinji Yasuno, Masakazu Toi
2013 ASCO Poster
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (JBCRG-13)
Kenji Higaki, Norikazu Masuda, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani,Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi
2013 ASCO Poster
Cohort study evaluating trastuzumab in HER2 positive early breast cancer in Japan; JBCRG-C01
Norikazu Masuda, Hiroyasu Yamashiro, Hiroji Iwata, Reiki Nishimura, Nobuaki Sato, Takako Kamio, T. Saito, Tecchuu Lee, Shinji Yasuno, Masakazu Toi
St Gallen 2013, 3
Inter-observer concordance of Ki-67 labeling index inbreast cancer[br]: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study
Takayuki Ueno, Yoshiki Mikami, Kenichi Yoshimura, Hitoshi Tsuda, Masafumi Kurosumi, Shinobu Masuda, Rie Horii, Masakazu Toi, and Hironobu Sasano
2012 SABCS Poster Session 5
A Prospective Multicenter Randomized Phase II Neo-Adjuvant Study of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Docetaxel, Cyclophosphamide and Trastuzumab (TCH) Versus TCH Followed by FEC Versus TCH Alone, in Patients (pts) with Operable HER2 Positive Breast Cancer: JBCRG-10 Study
Norikazu Masuda, Nobuaki Sato, Kenji Higaki, Masahiro Kashiwaba, Nobuki Matsunami, Toshimi Takano, Jun Yamamura, Koji Kaneko, Masato Takahashi, Shinji Ohno, Tomomi Fujisawa, Shigeru Tsuyuki, Yasuo Miyoshi, Shoichiro Ohtani, Yutaka Yamamoto, Hiroko Bando, Toshinao Onoda, Hidetaka Kawabata, Satoshi Morita, Takayuki Ueno, Masakazu Toi
2012 SABCS Poster Session 1
JBCRG10年のあゆみと展望
黒井克昌
広島大学医学部 広仁会館2階 大会議室
A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): the efficacy and its correlation with circulating endothelial cells
上野貴之、増田慎三、神垣俊二、森本卓、中村清吾、黒井克昌、岩田広治、大野真司、田中直、戸井雅和
2011 American Society of Clinical Oncology, Chicago (USA), Jun. 2011